Difference between revisions of "Leucovorin (Folinic acid)"
m |
m (Jwarner moved page Folinic acid (Leucovorin) to Leucovorin (Folinic acid): Alignment with INN) |
||
(13 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
==General information== | ==General information== | ||
− | Class/mechanism: Folic acid analog; counteracts the effects of folic acid antagonists such as methotrexate, which acts by inhibiting dihydrofolate reductase. | + | Class/mechanism: Folic acid analog; counteracts the effects of folic acid antagonists such as methotrexate, which acts by inhibiting dihydrofolate reductase. Enhances the activity of [[Fluorouracil (5-FU)]] by inhibiting thymidylate synthase.<ref name="insert">[https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208723s000lbl.pdf Leucovorin (Folinic acid) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/folinicacid.pdf Leucovorin (Folinic acid) package insert (locally hosted backup)]</ref> |
<br>Route: PO, IM, IV | <br>Route: PO, IM, IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
+ | |||
+ | ==Diseases for which it is established ''(work in progress)''== | ||
+ | ''Note: these are diseases where folinic acid is used as an adjuvant to [[Fluorouracil (5-FU)]], as opposed to an antidote as it is used in conjunction with [[Methotrexate (MTX)]]'' | ||
+ | *[[Colorectal cancer]] | ||
+ | **[[Colon cancer]] | ||
+ | **[[Rectal cancer]] | ||
+ | *[[Hepatocellular carcinoma]] | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
''Note: these are diseases where folinic acid is used as an adjuvant to [[Fluorouracil (5-FU)]], as opposed to an antidote as it is used in conjunction with [[Methotrexate (MTX)]]'' | ''Note: these are diseases where folinic acid is used as an adjuvant to [[Fluorouracil (5-FU)]], as opposed to an antidote as it is used in conjunction with [[Methotrexate (MTX)]]'' | ||
+ | *[[Anal cancer]] | ||
*[[Cervical cancer]] | *[[Cervical cancer]] | ||
*[[Cholangiocarcinoma]] | *[[Cholangiocarcinoma]] | ||
− | |||
*[[Esophageal cancer]] | *[[Esophageal cancer]] | ||
− | *[[ | + | **[[Esophageal adenocarcinoma]] |
− | *[[ | + | *[[Gallbladder cancer]] |
− | *[[ | + | *[[Gastric cancer]] |
− | *[[ | + | *[[Pancreatic cancer]] |
==Diseases for which it was used== | ==Diseases for which it was used== | ||
Line 23: | Line 30: | ||
==Patient drug information== | ==Patient drug information== | ||
− | *[https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208723s000lbl.pdf Folinic acid | + | *[https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208723s000lbl.pdf Leucovorin (Folinic acid) package insert]<ref name="insert"></ref> |
− | *[http://chemocare.com/bio/folinic_acid.asp Folinic acid | + | *[http://chemocare.com/bio/folinic_acid.asp Leucovorin (Folinic acid) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/folinic_acid.asp Leucovorin (Folinic acid) patient drug information (Chemocare)]</ref> |
− | *[http://www.uptodate.com/contents/leucovorin-patient-drug-information Folinic acid | + | *[http://www.uptodate.com/contents/leucovorin-patient-drug-information Leucovorin (Folinic acid) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/leucovorin-patient-drug-information Leucovorin (Folinic acid) patient drug information (UpToDate)]</ref> |
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
− | * | + | * 1952-06-20: Initial FDA approval |
− | * Indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced [[ | + | * Uncertain date: Indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced [[colorectal cancer]]. ''(Based on O'Connell 1989 & Poon et al. 1989)'' |
==Also known as== | ==Also known as== | ||
− | *'''Generic names:''' citrovorum factor, folinate calcium, folinato de calcio, leucovorin calcium, LV, sodium folinate | + | *'''Generic names:''' calcium folinate, citrovorum factor, folinate calcium, folinato de calcio, folinic acid, leucovorin calcium, LV, sodium folinate |
*'''Brand names:''' | *'''Brand names:''' | ||
{| class="wikitable" style="text-align:center;" | {| class="wikitable" style="text-align:center;" | ||
Line 47: | Line 54: | ||
|- | |- | ||
|Calcium Folint | |Calcium Folint | ||
− | |||
|Calcium Leucovorn | |Calcium Leucovorn | ||
|Calcivoran | |Calcivoran | ||
Line 54: | Line 60: | ||
|Calfolin | |Calfolin | ||
|Calinat | |Calinat | ||
+ | |Cehafolin | ||
|- | |- | ||
− | |||
|Citofolin | |Citofolin | ||
|Claro | |Claro | ||
Line 63: | Line 69: | ||
|Divifolin | |Divifolin | ||
|Durofolin | |Durofolin | ||
+ | |Ecofol | ||
|- | |- | ||
− | |||
|Elvefocal | |Elvefocal | ||
|Emovis | |Emovis | ||
Line 72: | Line 78: | ||
|Fauldleuco | |Fauldleuco | ||
|Fayining | |Fayining | ||
+ | |Fedolen | ||
|- | |- | ||
− | |||
|Ferbon | |Ferbon | ||
|Folaren | |Folaren | ||
Line 81: | Line 87: | ||
|Folidan | |Folidan | ||
|Folidar | |Folidar | ||
+ | |Foliment | ||
|- | |- | ||
− | |||
|Folinac | |Folinac | ||
|Folinato | |Folinato | ||
Line 90: | Line 96: | ||
|Folinvit | |Folinvit | ||
|Foliplus | |Foliplus | ||
+ | |Folmigor | ||
|- | |- | ||
− | |||
|Ifavor | |Ifavor | ||
|Isovorin | |Isovorin | ||
Line 99: | Line 105: | ||
|Lederfolat | |Lederfolat | ||
|Lederfolin | |Lederfolin | ||
+ | |Lederfoline | ||
|- | |- | ||
− | |||
|Ledervorin | |Ledervorin | ||
|Legifol | |Legifol | ||
Line 106: | Line 112: | ||
|Leuconolver | |Leuconolver | ||
|Leucosar | |Leucosar | ||
− | |||
|Leucovorina | |Leucovorina | ||
− | |||
|Leucovorine | |Leucovorine | ||
|Leukovorin | |Leukovorin | ||
+ | |- | ||
|Lovorin | |Lovorin | ||
|Medicofolin | |Medicofolin | ||
Line 117: | Line 122: | ||
|Neofolin | |Neofolin | ||
|Nyrin | |Nyrin | ||
− | |||
|O Folin | |O Folin | ||
|Osfolate | |Osfolate | ||
+ | |- | ||
|Osfolato | |Osfolato | ||
|Perfolate | |Perfolate | ||
Line 126: | Line 131: | ||
|Recovorin | |Recovorin | ||
|Reotan | |Reotan | ||
− | |||
|Rescuvolin | |Rescuvolin | ||
|Resfolin | |Resfolin | ||
+ | |- | ||
|Ribofolin | |Ribofolin | ||
|Rontafor | |Rontafor | ||
Line 135: | Line 140: | ||
|Tonofolin | |Tonofolin | ||
|Veravorin | |Veravorin | ||
− | |||
|Vorina | |Vorina | ||
|Wellcovorin | |Wellcovorin | ||
+ | |- | ||
|Zyofolin | |Zyofolin | ||
|Zytofolin | |Zytofolin | ||
Line 151: | Line 156: | ||
[[Category:Chemotherapy protective agents]] | [[Category:Chemotherapy protective agents]] | ||
+ | [[Category:Folic acid analog]] | ||
+ | |||
+ | [[Category:Anal cancer medications]] | ||
[[Category:Cervical cancer medications]] | [[Category:Cervical cancer medications]] | ||
[[Category:Cholangiocarcinoma medications]] | [[Category:Cholangiocarcinoma medications]] | ||
+ | [[Category:Colorectal cancer medications]] | ||
[[Category:Colon cancer medications]] | [[Category:Colon cancer medications]] | ||
+ | [[Category:Esophageal adenocarcinoma medications]] | ||
[[Category:Esophageal cancer medications]] | [[Category:Esophageal cancer medications]] | ||
+ | [[Category:Gallbladder cancer medications]] | ||
[[Category:Gastric cancer medications]] | [[Category:Gastric cancer medications]] | ||
[[Category:Hepatocellular carcinoma medications]] | [[Category:Hepatocellular carcinoma medications]] |
Latest revision as of 15:22, 29 September 2023
General information
Class/mechanism: Folic acid analog; counteracts the effects of folic acid antagonists such as methotrexate, which acts by inhibiting dihydrofolate reductase. Enhances the activity of Fluorouracil (5-FU) by inhibiting thymidylate synthase.[1][2]
Route: PO, IM, IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is established (work in progress)
Note: these are diseases where folinic acid is used as an adjuvant to Fluorouracil (5-FU), as opposed to an antidote as it is used in conjunction with Methotrexate (MTX)
Diseases for which it is used
Note: these are diseases where folinic acid is used as an adjuvant to Fluorouracil (5-FU), as opposed to an antidote as it is used in conjunction with Methotrexate (MTX)
- Anal cancer
- Cervical cancer
- Cholangiocarcinoma
- Esophageal cancer
- Gallbladder cancer
- Gastric cancer
- Pancreatic cancer
Diseases for which it was used
Note: these are diseases where folinic acid is used as an adjuvant to Fluorouracil (5-FU), as opposed to an antidote as it is used in conjunction with Methotrexate (MTX)
Patient drug information
- Leucovorin (Folinic acid) package insert[1]
- Leucovorin (Folinic acid) patient drug information (Chemocare)[3]
- Leucovorin (Folinic acid) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1952-06-20: Initial FDA approval
- Uncertain date: Indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. (Based on O'Connell 1989 & Poon et al. 1989)
Also known as
- Generic names: calcium folinate, citrovorum factor, folinate calcium, folinato de calcio, folinic acid, leucovorin calcium, LV, sodium folinate
- Brand names:
Synonyms | |||||||
---|---|---|---|---|---|---|---|
Antrex | Asovorin | Biovorin | Buateron | Calcifolin | Calciumfolin | Calciumfolinat | Calcium Folinato |
Calcium Folint | Calcium Leucovorn | Calcivoran | Calc Leucovorn | Calfolex | Calfolin | Calinat | Cehafolin |
Citofolin | Claro | Cromatonbic Folinico | Dalisol | Degalin | Divifolin | Durofolin | Ecofol |
Elvefocal | Emovis | Erbanfol | Estroquin | Fastovorin | Fauldleuco | Fayining | Fedolen |
Ferbon | Folaren | Folaxin | Foliben | Foli Cell | Folidan | Folidar | Foliment |
Folinac | Folinato | Folinfabra | Folinoral | Folinoxan | Folinvit | Foliplus | Folmigor |
Ifavor | Isovorin | Kalciumfolinat Perivita | Kalsiumfolinat | Kunyrin | Lederfolat | Lederfolin | Lederfoline |
Ledervorin | Legifol | Leucocalcin | Leuconolver | Leucosar | Leucovorina | Leucovorine | Leukovorin |
Lovorin | Medicofolin | Medifolin | Medsavorina | Neofolin | Nyrin | O Folin | Osfolate |
Osfolato | Perfolate | Prefolic | Prevax | Recovorin | Reotan | Rescuvolin | Resfolin |
Ribofolin | Rontafor | Sanifolin | Tecnovorin | Tonofolin | Veravorin | Vorina | Wellcovorin |
Zyofolin | Zytofolin |
References
- Drugs
- Intramuscular medications
- Intravenous medications
- Oral medications
- Chemotherapy protective agents
- Folic acid analog
- Anal cancer medications
- Cervical cancer medications
- Cholangiocarcinoma medications
- Colorectal cancer medications
- Colon cancer medications
- Esophageal adenocarcinoma medications
- Esophageal cancer medications
- Gallbladder cancer medications
- Gastric cancer medications
- Hepatocellular carcinoma medications
- Pancreatic cancer medications
- Rectal cancer medications
- Breast cancer medications (historic)
- FDA approved in 1952
- WHO Essential Cancer Medicine